Skip to content
Medical Health Aged Care

Dementia Australia supports Esperance

Dementia Australia 2 mins read

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Esperance between 24 and 29 February. 

It is estimated there are almost 41,400 people living with dementia in Western Australia. Without a medical breakthrough this number is expected to increase to more than 86,800 people living with dementia by 2054. 

These Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia can provide. Please note, bookings are essential. 

Understanding Changes in Behaviour  

This session provides an introduction to dementia and changes to the brain, effects on behaviour and the impacts of changed behaviour. 

  • Monday 26 February 9:30am-12:30pm   

Dementia Essentials (for professionals) 

This session will provide orientation and training for good communication, applying person-centred principles and help create a supportive environment for people living with dementia.  

  • Monday 26 February – Thursday 29 February, 11am-4:30pm everyday

It Starts With You 

If you are passionate about your local community and want to make it more dementia-friendly then this session is for you.  

  • Monday 26 February 5:30pm-7:00pm 

Activities at Home  

This practical session assists carers looking after someone at home with ideas for engaging activities.  

  • Tuesday 27 February 9:30am-12:00pm 

Bookings are essential. Visit https://www.dementia.org.au/brainhub/esperance for details and to register. You can also call the National Dementia Helpline to register for this course on 1800 100 500. The National Dementia Helpline is available 24 hours a day, seven days a week. 

  

Dementia Australia is the source of trusted information, education and services for the estimated more than 400,000 Australians living with dementia, and the more than 1.5 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you. 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au  

-Ends- 

Media contacts: Andrea Hogan, Manager Media and Communications, Andrea.Hogan@dementia.org.au, 0406 904 118 

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines. 

Note to Editors: 

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:  

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au 

 

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.